HUDSON, N.H., March 12 /PRNewswire/ -- Atrium Medical Corporation announced today that it has received CE Mark for a new small vessel therapeutic perfusion catheter called ClearWay(TM) RX. ClearWay RX is indicated for localized delivery of therapeutic agents to the coronary and peripheral vasculature.
ClearWay(TM) RX is the world’s first Rapid Exchange therapeutic perfusion catheter for localized therapeutic delivery within small caliber vessels. Delivering a smaller quantity of a preferred therapeutic agent locally has been shown to help reduce systemic effects. ClearWay RX is a low pressure perfusion catheter which incorporates a thin, semi-compliant microporous PTFE balloon material to deliver small quantities of medication. This patented microporous balloon allows for controlled infusion at very low pressures (2 - 4atm) for maximum local therapeutic effect at a discrete targeted location. The rapid exchange perfusion catheter is .014" guidewire compatible, allowing access to several difficult to reach target destinations throughout the body. ClearWay RX will be available in 1.0 to 4.0 mm balloon diameters and in balloon lengths ranging from 10 to 50 mm. Longer balloon lengths provide for a wide range of local tissue treatment options with a single therapeutic perfusion inflation.
ClearWay RX is the latest advance in a series of unique medical device innovations, built on a 25 year heritage of excellence in advanced polymer and biomaterial science at Atrium. This late breaking interventional drug delivery technology creates a novel approach for several promising new pharmaceutical agents which may prove beneficial with more localized delivery with far less systemic payloads.
About Atrium
Atrium’s vast expertise in developing medical device technologies for the treatment of soft tissue repair, heart disease and adhesion prevention has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, hernia and soft tissue repair. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of- the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in several specialty healthcare markets requiring surgical intervention. For more information call 800-370-7899 or visit Atrium’s website www.atriummed.com
Source: Atrium Medical Corporation
